

1.

Dominguez-Valentin M, Sampson JR, Seppala TT, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. *Genet Med.* July 2019. doi:[10.1038/s41436-019-0596-9](https://doi.org/10.1038/s41436-019-0596-9)

2.

Morak M, Schaefer K, Steinke-Lange V, et al. Full-length transcript amplification and sequencing as universal method to test mRNA integrity and biallelic expression in mismatch repair genes. *Eur J Hum Genet.* July 2019. doi:[10.1038/s41431-019-0472-8](https://doi.org/10.1038/s41431-019-0472-8)

3.

Ten Broeke SW, Rodriguez-Girondo M, Suerink M, et al. The Apparent Genetic Anticipation in PMS2-Associated Lynch Syndrome Families Is Explained by Birth-cohort Effect. *Cancer Epidemiol Biomarkers Prev.* 2019;28(6):1010-1014. doi:[10.1158/1055-9965.EPI-18-0576](https://doi.org/10.1158/1055-9965.EPI-18-0576)

4.

Seppala TT, Ahadova A, Dominguez-Valentin M, et al. Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. *Hered Cancer Clin Pract.* 2019;17:8. doi:[10.1186/s13053-019-0106-8](https://doi.org/10.1186/s13053-019-0106-8)

5.

Kayser K, Degenhardt F, Holzapfel S, et al. Copy number variation analysis and targeted NGS in 77 families with suspected Lynch syndrome reveals novel potential causative genes. *Int J Cancer.* 2018;143(11):2800-2813. doi:[10.1002/ijc.31725](https://doi.org/10.1002/ijc.31725)

6.

Engel C, Vasen HF, Seppala T, et al. No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies. *Gastroenterology.* 2018;155(5):1400-1409.e2. doi:[10.1053/j.gastro.2018.07.030](https://doi.org/10.1053/j.gastro.2018.07.030)

7.

Emons G, Steiner E, Vordermark D, et al. Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) - Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities. *Geburtshilfe Frauenheilkd.* 2018;78(11):1089-1109. doi:[10.1055/a-0715-2964](https://doi.org/10.1055/a-0715-2964)

8.

Ten Broeke SW, van der Klift HM, Tops CMJ, et al. Cancer Risks for PMS2-Associated Lynch Syndrome. *J Clin Oncol*. 2018;36(29):2961-2968. doi:[10.1200/JCO.2018.78.4777](https://doi.org/10.1200/JCO.2018.78.4777)

9.

Emons G, Steiner E, Vordermark D, et al. Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer. *Geburtshilfe Frauenheilkd*. 2018;78(10):949-971. doi:[10.1055/a-0713-1218](https://doi.org/10.1055/a-0713-1218)

10.

Sill H, Schulz E, Steinke-Lange V, Boland CR. Correspondence: Reply to “SEMA4A variation and risk of colorectal cancer”. *Nat Commun*. 2016;7:10695. doi:[10.1038/ncomms10695](https://doi.org/10.1038/ncomms10695)

11.

Spier I, Holzapfel S, Altmüller J, et al. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. *Int J Cancer*. 2015;137(2):320-331. doi:[10.1002/ijc.29396](https://doi.org/10.1002/ijc.29396)

12.

Horpaopan S, Spier I, Zink AM, et al. Genome-wide CNV analysis in 221 unrelated patients and targeted high-throughput sequencing reveal novel causative candidate genes for colorectal adenomatous polyposis. *Int J Cancer*. 2015;136(6):E578-589. doi:[10.1002/ijc.29215](https://doi.org/10.1002/ijc.29215)

13.

Hinrichsen I, Schafer D, Langer D, et al. Functional testing strategy for coding genetic variants of unclear significance in MLH1 in Lynch syndrome diagnosis. *Carcinogenesis*. 2015;36(2):202-211. doi:[10.1093/carcin/bgu239](https://doi.org/10.1093/carcin/bgu239)

14.

Schulz E, Klampfl P, Holzapfel S, et al. Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X. *Nat Commun*. 2014;5:5191. doi:[10.1038/ncomms6191](https://doi.org/10.1038/ncomms6191)

15.

Steinke V, Holzapfel S, Loeffler M, et al. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families. *Int J Cancer*. 2014;135(1):69-77. doi:[10.1002/ijc.28650](https://doi.org/10.1002/ijc.28650)

16.

Yang R, Chen B, Pfütze K, et al. Genome-wide analysis associates familial colorectal cancer with increases in copy number variations and a rare structural variation at 12p12.3. *Carcinogenesis*. 2014;35(2):315-323. doi:[10.1093/carcin/bgt344](https://doi.org/10.1093/carcin/bgt344)

17.

Hinrichsen I, Ernst BP, Nuber F, et al. Reduced migration of MLH1 deficient colon cancer cells depends on SPTAN1. *Mol Cancer*. 2014;13:11. doi:[10.1186/1476-4598-13-11](https://doi.org/10.1186/1476-4598-13-11)

18.

Smith CG, West H, Harris R, et al. Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis. *J Natl Cancer Inst*. 2013;105(16):1249-1253. doi:[10.1093/jnci/djt183](https://doi.org/10.1093/jnci/djt183)

19.

Steinke V, Engel C, Buttner R, Schackert HK, Schmiegel WH, Propping P. Hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch syndrome. *Dtsch Arztebl Int*. 2013;110(3):32-38. doi:[10.3238/arztebl.2013.0032](https://doi.org/10.3238/arztebl.2013.0032)

20.

Rahner N, Steinke V, Schlegelberger B, Eisinger F, Hutter P, Olschwang S. Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) - update 2012. *Eur J Hum Genet*. 2013;21(1). doi:[10.1038/ejhg.2012.164](https://doi.org/10.1038/ejhg.2012.164)

21.

Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. *J Clin Oncol*. 2012;30(35):4409-4415. doi:[10.1200/JCO.2012.43.2278](https://doi.org/10.1200/JCO.2012.43.2278)

22.

Rahner N, Brockschmidt FF, Steinke V, et al. Mutation and association analyses of the candidate genes ESR1, ESR2, MAX, PCNA, and KAT2A in patients with unexplained MSH2-deficient tumors. *Fam Cancer*. 2012;11(1):19-26. doi:[10.1007/s10689-011-9489-z](https://doi.org/10.1007/s10689-011-9489-z)

23.

Gullotti L, Czerwitzki J, Kirfel J, et al. FHL2 expression in peritumoural fibroblasts correlates with lymphatic metastasis in sporadic but not in HNPCC-associated colon cancer. *Lab Invest*. 2011;91(12):1695-1705. doi:[10.1038/labinvest.2011.109](https://doi.org/10.1038/labinvest.2011.109)

24.

Morak M, Koehler U, Schackert HK, et al. Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome. *J Med Genet*. 2011;48(8):513-519. doi:[10.1136/jmedgenet-2011-100050](https://doi.org/10.1136/jmedgenet-2011-100050)

25.

Hardt K, Heick SB, Betz B, et al. Missense variants in hMLH1 identified in patients from the German HNPCC consortium and functional studies. *Fam Cancer*. 2011;10(2):273-284. doi:[10.1007/s10689-011-9431-4](https://doi.org/10.1007/s10689-011-9431-4)

26.

Kuiper RP, Vissers LELM, Venkatachalam R, et al. Recurrence and variability of germline EPCAM deletions in Lynch syndrome. *Hum Mutat*. 2011;32(4):407-414. doi:[10.1002/humu.21446](https://doi.org/10.1002/humu.21446)

27.

Huhn S, Ingelfinger D, Bermejo JL, et al. Polymorphisms in CTNNB1 in relation to colorectal cancer with evolutionary implications. *Int J Mol Epidemiol Genet*. 2011;2(1):36-50.

28.

Kempers MJE, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. *Lancet Oncol*. 2011;12(1):49-55. doi:[10.1016/S1470-2045\(10\)70265-5](https://doi.org/10.1016/S1470-2045(10)70265-5)

29.

Carrai M, Steinke V, Vodicka P, et al. Association between TAS2R38 gene polymorphisms and colorectal cancer risk: a case-control study in two independent populations of Caucasian origin. *PLoS One*. 2011;6(6):e20464. doi:[10.1371/journal.pone.0020464](https://doi.org/10.1371/journal.pone.0020464)

30.

Campa D, Pardini B, Naccarati A, et al. Polymorphisms of genes coding for ghrelin and its receptor in relation to colorectal cancer risk: a two-step gene-wide case-control study. *BMC Gastroenterol*. 2010;10:112. doi:[10.1186/1471-230X-10-112](https://doi.org/10.1186/1471-230X-10-112)

31.

Rahner N, Steinke V, Schlegelberger B, Olschwang S, Eisinger F, Hutter P. Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2). *Eur J Hum Genet*. 2010;18(9). doi:[10.1038/ejhg.2009.232](https://doi.org/10.1038/ejhg.2009.232)

32.

Lascorz J, Forsti A, Chen B, et al. Genome-wide association study for colorectal cancer identifies risk polymorphisms in German familial cases and implicates MAPK signalling pathways in disease susceptibility. *Carcinogenesis*. 2010;31(9):1612-1619. doi:[10.1093/carcin/bgq146](https://doi.org/10.1093/carcin/bgq146)

33.

Engel C, Rahner N, Schulmann K, et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. *Clin Gastroenterol Hepatol.* 2010;8(2):174-182. doi:[10.1016/j.cgh.2009.10.003](https://doi.org/10.1016/j.cgh.2009.10.003)

34.

Vogt S, Jones N, Christian D, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. *Gastroenterology.* 2009;137(6):1976-1985.e1-10. doi:[10.1053/j.gastro.2009.08.052](https://doi.org/10.1053/j.gastro.2009.08.052)

35.

Papaemmanuil E, Carvajal-Carmona L, Sellick GS, et al. Deciphering the genetics of hereditary non-syndromic colorectal cancer. *Eur J Hum Genet.* 2008;16(12):1477-1486. doi:[10.1038/ejhg.2008.129](https://doi.org/10.1038/ejhg.2008.129)

36.

Rahner N, Steinke V. Hereditary cancer syndromes. *Dtsch Arztebl Int.* 2008;105(41):706-714. doi:[10.3238/arztebl.2008.0706](https://doi.org/10.3238/arztebl.2008.0706)

37.

Rahner N, Hoefler G, Hogenauer C, et al. Compound heterozygosity for two MSH6 mutations in a patient with early onset colorectal cancer, vitiligo and systemic lupus erythematosus. *Am J Med Genet A.* 2008;146A(10):1314-1319. doi:[10.1002/ajmg.a.32210](https://doi.org/10.1002/ajmg.a.32210)

38.

Steinke V, Rahner N, Morak M, et al. No association between MUTYH and MSH6 germline mutations in 64 HNPCC patients. *Eur J Hum Genet.* 2008;16(5):587-592. doi:[10.1038/ejhg.2008.26](https://doi.org/10.1038/ejhg.2008.26)

39.

Rahner N, Friedrichs N, Wehner M, et al. Nine novel pathogenic germline mutations in MLH1, MSH2, MSH6 and PMS2 in families with Lynch syndrome. *Acta Oncol.* 2007;46(6):763-769. doi:[10.1080/02841860701230217](https://doi.org/10.1080/02841860701230217)